amgen_hq

Amgen’s patent win upheld against Sanofi-Regeneron

pharmafile | January 4, 2017 | News story | Medical Communications, Research and Development Amgen, Regeneron, Sanofi, patent 

In March 2016, Amgen won two major patent cases against Sanofi and Regeneron over their drug, Praleunt, after it was found to infringe Amgen’s patents. Sanofi and Regeneron sought to overturn the verdict and create a new trial over the case, but this appeal was dismissed by US district judge Sue Robinson.

The decision will come as a blow to Sanofi and Regeneron, depending on further decisions from Robinson. Damages that would have to be paid to Amgen have yet to be set and there is still a decision to be made regarding whether Prauleunt will be blocked from the market. Sanofi and Regeneron plan to take the case to the Court of Appeals.

“The court’s ruling today is an important step in this case and confirms the jury’s finding that the patents which protect Repatha are valid and infringed by Sanofi,” Amgen spokeswoman Kristen Davis is reported as commenting Reuters.

Amgen case had been brought after it determined that Sanofi and Regeneron’s Praleunt infringed upon its own drug’s, Repatha, patents. Both drugs were approved in the summer of 2015, with similar list prices and similar labels.

The drugs are used to reduce ‘bad cholesterol’ from being made by blocking the PCSK9 protein. This is the crux on which the case rests, with Amgen claiming that the infringement lies upon the action of the drug upon the protein.

Ben Hargreaves

Related Content

Sanofi shares phase 2b results for dermatitis treatment

Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …

Amgen opens new biomanufacturing facility in Ohio, US

Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …

FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review

Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its …

Latest content